Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression.,Journal of Diabetes Investigation

当前位置： X-MOL 学术 › J. Diabetes Investig. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression.
Journal of Diabetes Investigation ( IF 3.1 ) Pub Date : 2020-04-09 , DOI: 10.1111/jdi.13247
Toru Shigeoka ₁ , Takashi Nomiyama _{1,

2} , Takako Kawanami ₁ , Yuriko Hamaguchi ₁ , Tsuyoshi Horikawa ₁ , Tomoko Tanaka ₁ , Shinichiro Irie ₃ , Ryoko Motonaga ₁ , Nobuya Hamanoue ₁ , Makito Tanabe ₁ , Kazuki Nabeshima ₄ , Masatoshi Tanaka ₃ , Toshihiko Yanase _{2,

5} , Daiji Kawanami ₁

Affiliation

Incretin therapy is a common treatment for type 2 diabetes mellitus. We have previously reported an anti‐prostate cancer effect of glucagon‐like peptide‐1 receptor (GLP‐1R) agonist exendin‐4. The attenuation of cell proliferation in the prostate cancer cell line was dependent on GLP‐1R expression. Here, we examined the relationship between human prostate cancer severity and GLP‐1R expression, as well as the effect of forced expression of GLP‐1R using a lentiviral vector.

中文翻译：

过度表达的胰高血糖素样肽 1 受体的激活通过抑制细胞周期进程来减弱前列腺癌的生长。

肠促胰岛素治疗是 2 型糖尿病的常见治疗方法。我们之前报道过胰高血糖素样肽-1受体（GLP-1R）激动剂exendin-4具有抗前列腺癌作用。前列腺癌细胞系中细胞增殖的减弱取决于 GLP-1R 的表达。在这里，我们研究了人类前列腺癌严重程度与 GLP-1R 表达之间的关系，以及使用慢病毒载体强制表达 GLP-1R 的效果。

更新日期：2020-04-09

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11